Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Madrigal Pharmaceuticals (MDGL) Debt to Equity (2022 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Debt to Equity for 10 consecutive years, with $0.56 as the latest value for Q4 2025.

  • Quarterly Debt to Equity rose 261.85% to $0.56 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $0.56 through Dec 2025, up 261.85% year-over-year, with the annual reading at $0.56 for FY2025, 261.85% up from the prior year.
  • Debt to Equity for Q4 2025 was $0.56 at Madrigal Pharmaceuticals, up from $0.54 in the prior quarter.
  • The five-year high for Debt to Equity was $5.16 in Q3 2023, with the low at $0.14 in Q2 2024.
  • Average Debt to Equity over 4 years is $0.96, with a median of $0.28 recorded in 2023.
  • The sharpest move saw Debt to Equity tumbled 97.08% in 2024, then skyrocketed 261.85% in 2025.
  • Over 4 years, Debt to Equity stood at $0.25 in 2022, then grew by 14.1% to $0.28 in 2023, then plummeted by 45.3% to $0.16 in 2024, then surged by 261.85% to $0.56 in 2025.
  • According to Business Quant data, Debt to Equity over the past three periods came in at $0.56, $0.54, and $0.17 for Q4 2025, Q3 2025, and Q2 2025 respectively.